W. R. Grace artificial liver
This article was originally published in The Gray Sheet
Executive Summary
W. R. Grace and Cedars-Sinai Medical Center of Los Angeles begin clinical study of a bioartificial liver system following FDA approval of an investigational new drug application for the system. The bioartificial liver, developed jointly by Grace and Cedars under an agreement announced in November ("The Gray Sheet" Nov. 22, 1993, In Brief), consists of "a hollow-fiber membrane cartridge filled with a matrix of pig liver cells" and is intended to act as a short-term bridge to transplant for patients with acute and chronic liver failure. The first phase of the trial will involve 12-20 patients and will take place at Cedars, with Phase II trials expected to begin in mid-1995
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.